Disseminated cryptococcosis, invasive aspergillosis, and mucormycosis in a patient treated with alemtuzumab for chronic lymphocytic leukaemia.
We report the case of a 42-y-old man treated with alemtuzumab for chronic lymphocytic leukaemia, who developed 3 successive deep fungal infections. Despite being treated with liposomal amphotericin B and 5-flucytosine for disseminated cryptococcosis, he developed pulmonary invasive aspergillosis, followed by pulmonary mucormycosis. Several deep fungal infections may occur in association in an immunocompromised host after treatment with alemtuzumab.
From the Infectious and Tropical Diseases Department , Paris , France.
Aurélia
A
Henn
Guillaume
G
Mellon
Henry
H
Benoît
Damien
D
Roos-Weil
Stéphane
S
Jauréguiberry
Pierre
P
Mordant
Arnaud
A
Fekkar
Eric
E
Caumes
D000328:Adult; D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000382:microbiology*; D008297:Male; D009181:Mycoses / Q000139:chemically induced*; D013902:Radiography, Thoracic; D014057:Tomography, X-Ray Computed
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000074323:Alemtuzumab